The crude HRs for those using sodium glucose transporter 2 inhibitors (SGLT2i) were elevated, but the statistical significance vanished with adjustment for age, sex, diabetes duration, and treatment year in both groups (with additional insulin therapy and those without insulin treatment). This evidence concerns the gene INS and diabetes mellitus.